Berlin Heart GmbH
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Berlin Heart GmbH
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
As part of a periodic review, FDA is bringing together experts to review several products that are conditionally available for pediatric use under the agency's Humanitarian Device Exemption program.
A Pediatric Advisory Committee meeting is planned for Sept. 14 to assess safety data for five devices used in children, and almost a dozen other drugs and biologics.
- Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
- Berlin Heart Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.